Metabasis Therapeutics, Inc.’ Results from Its Phase 2a Clinical Trial for MB07803 to Be Presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company’s Phase 2a clinical trial for MB07803 will be given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), to be held in Barcelona, Spain, October 30 to November 2, 2008. MB07803 is the Company’s second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor for the treatment of type 2 diabetes.